Biolidics Limited

8YY

SGXE89830751

Advanced Medical Equipment & Technology

Market Closed - Singapore S.E. Other stock markets 10:04:32 12/09/2024 BST			5-day change	1st Jan Change
0.009000 ^SGD	-10.00%		-10.00%	-35.71%

08-26	Biolidics Amends Share Subscription Agreement with Chairman	MT
08-13	Biolidics Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Biolidics Limited

Biolidics Amends Share Subscription Agreement with Chairman	08-26	MT
Biolidics Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-13	CI
Singapore Shares Tumble as Retail Sales Drop; Biolidics Plunges 10%	08-05	MT
Biolidics Enters Supplemental Agreement Tied to Shenzhen Network Technology Acquisition; Biolidics Shares Plummet 10%	08-05	MT
Biolidics Incorporates Two Subsidiaries	08-01	MT
Biolidics Limited Announces Incorporation of Subsidiary Companies	07-31	CI
Biolidics to Buy Shenzhen Xiaozhao Network; Secures SG$1.5 Million Loan	07-25	MT
Biolidics Limited agreed to acquire Shenzhen Xiaozhao Network Technology Co., Ltd from Dreamsgame Inc. for SGD 4.1 million.	07-23	CI
Biolidics Names Ex-Weiye Executive as Financial Controller	06-28	MT
Biolidics Limited Appoints Mr. Lau Wei Kian as the Financial Controller, Effective July 01, 2024	06-27	CI
Biolidics’ CEO Steps Down; Shares Surge 10%	06-17	MT
Biolidics Limited Announces Board Changes	06-14	CI
Biolidics Limited Announces Chief Executive Officer Changes	06-14	CI
Biolidics Places Subsidiary Under Voluntary Liquidation	06-10	MT
Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR	06-04	CI
Bioldics' Financial Controller Steps Down	05-20	MT
Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller	05-17	CI
Singapore Shares Drop in Red Despite Global Rally; Biolidics Surges 20% on Wider Losses in Q1	05-15	MT
Biolidics' Q1 Loss Widens as Revenue Slumps; Stock Surges 20%	05-15	MT
Biolidics Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Biolidics Flags Cybersecurity Incident; Shares Surge 10%	05-10	MT
Biolidics Appoints President	05-02	MT
Biolidics Limited Announces the Appointment of Executive Director and President and Changes to the Composition of the Board	05-02	CI
Biolidics Limited Announces Board Changes	04-30	CI
Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director	04-12	CI

Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. It has three segments: Cancer, Infectious diseases, and Laboratory services. Its Cancer and infectious diseases segments involve the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the cancer field, and the infectious diseases field. The laboratory services segment involves the business, operation, and provision of laboratory services to customers. The laboratory has a regulatory approval from Singaporeâs Ministry of Health for molecular microbiology testing for COVID-19 in Singapore.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

27/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company